Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage I Lung Cancer Clear all
Completed Phase 2 Interventional

Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery

NCT00281970
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, adjuvant therapy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Jul 21, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00601094
View directory record Official record
Conditions
Lung Cancer
Interventions
autologous dendritic cell-adenovirus CCL21 vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 21, 2026, 9:24 PM EDT
Active, not recruiting Phase 1 Interventional

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339
View directory record Official record
Conditions
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions
NBTXR3, SABR, Nivolumab, Pembrolizumab
Drug · Radiation
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 21, 2026, 9:24 PM EDT
Recruiting Phase 2 Interventional

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

NCT06693336
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Interventions
SMS001
Drug
Lead sponsor
ToLymph Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

NCT01051934
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Adenocarcinoma
Interventions
SS1 (dsFv) PE38, Paclitaxel, Carboplatin, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 9:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

NCT04152499
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
Interventions
SKB264
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 21, 2026, 9:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

NCT02696993
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Cognitive Assessment, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Biological · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 21, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

NCT02581787
View directory record Official record
Conditions
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Interventions
Fresolimumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
Maximilian Diehn
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Jul 21, 2026, 9:24 PM EDT
Suspended Phase 1 Interventional

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

NCT04266730
View directory record Official record
Conditions
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
PANDA-VAC, Pembrolizumab
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

NCT00856830
View directory record Official record
Conditions
Small Cell Lung Cancer, Extensive Stage Lung Cancer, Chemonaive
Interventions
Novel Drug Combination
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Jul 21, 2026, 9:24 PM EDT
Completed Not applicable Interventional

Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer

NCT01741636
View directory record Official record
Conditions
Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions
educational intervention, questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 21, 2026, 9:24 PM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 21, 2026, 9:24 PM EDT
Active, not recruiting Phase 1 Interventional

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

NCT06077500
View directory record Official record
Conditions
Small Cell Lung Carcinoma (SCLC)
Interventions
BI 764532, Carboplatin, Etoposide, Atezolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional Results available

Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy

NCT00077064
View directory record Official record
Conditions
Lung Cancer, Pulmonary Complications, Radiation Fibrosis
Interventions
captopril
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
87
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Jul 21, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00003037
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Jul 21, 2026, 9:24 PM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02321501
View directory record Official record
Conditions
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 21, 2026, 9:24 PM EDT
Terminated Phase 1 Interventional

Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

NCT03321747
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Ablative Body Radiation (SABR)
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 21, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional Results available

Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer

NCT04515004
View directory record Official record
Conditions
Early Stage Lung Cancer (I and II)
Interventions
leucoselect phytosome
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 21, 2026, 9:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

NCT03974022
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sunvozertinib
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Whittier, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 21, 2026, 9:24 PM EDT
Terminated Phase 1 Interventional

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

NCT04911166
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Atezolizumab and Interleukin-12 Gene Therapy
Combination Product
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 21, 2026, 9:24 PM EDT
Completed No phase listed Observational

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

NCT00003329
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
gene mapping
Genetic
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
32
States / cities
Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 21, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

NCT00014430
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Jul 21, 2026, 9:24 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Vaccination of Advanced-Stage Lung Cancer Patients

NCT02264236
View directory record Official record
Conditions
Lung Neoplasms
Interventions
P10s-PADRE vaccine
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 21, 2026, 9:24 PM EDT
Terminated Phase 1Phase 2 Interventional

Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

NCT00264134
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Extensive Stage Unresectable
Interventions
Docetaxel, Irinotecan, Carboplatin
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 19, 2010 · Synced Jul 21, 2026, 9:24 PM EDT